Regenxbio company information, Employees & Contact Information

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD Yahoo Finance

1,200+ Enrolled: REGENXBIO Completes Largest Gene Therapy Wet AMD Program; Topline Q4 2026 Stock Titan

FDA Bumps Back PDUFA for REGENXBIO's MPS II Gene Therapy RGX-121 CGTLive®

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 PR Newswire

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting Yahoo Finance

Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year CGTLive®

2-Year Results: REGENXBIO Presents ALTITUDE Phase II Data for Diabetic Retinopathy Oct 17 Stock Titan

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment PR Newswire

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy Yahoo Finance

Promising DMD Gene Therapy: REGENXBIO's RGX-202 Shows Superior Results vs Natural History Controls Stock Titan

REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA CGTLive®

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire

REGENXBIO to Participate in Upcoming Investor Conferences Stock Titan

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial CGTLive®

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA PR Newswire

REGENXBIO to Reveal Q2 2025 Financial Results and Key Operational Updates on August 7 Stock Titan

REGENXBIO Doses First Patient in Phase 3 Trial for DMD Gene Therapy RGX-202 CGTLive®

First-Ever Gene Therapy for Hunter Syndrome: REGENXBIO's RGX-121 FDA Review Extended with New Data Stock Titan

82% Brain Disease Marker Drop: REGENXBIO's One-Time Hunter Syndrome Treatment Shows Promise in Pivotal Trial Stock Titan

REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility PR Newswire

REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD Ophthalmology Times

REGENXBIO’s MPSII Gene Therapy RGX-121 Continues to Show Efficacy in Long-Term Trial Data CGTLive®

Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation CGTLive®

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer citybiz

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium Stock Titan

Earnings call transcript: Regenxbio Q2 2025 misses forecasts, stock dips Investing.com

Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD HCPLive

RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies Fierce Biotech

Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes Fierce Biotech

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy BioPharma Dive

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) Seeking Alpha

What you missed at AAO 2024: ABBV-RGX-314 for wet AMD Modern Retina

Regenxbio: RGX-314 Continues Advancing With Solid Financials (NASDAQ:RGNX) Seeking Alpha

Beyond Rare Disease: Wet AMD Gene Therapy Could Reach Millions BioSpace

Editorial: Viral vector-based gene therapy in neurological disease: The future is now Frontiers

After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study Fierce Biotech

Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku BioSpace

REGENXBIO’s ABBV-RGX-314 Trials Aim to Reduce Treatment Burden in Inherited Retinal Diseases CGTLive®

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Regenxbio (NASDAQ:RGNX) Benzinga

Regenxbio-AbbVie in-office eye disease gene therapy clears interim phase 2 test Fierce Biotech

Expert Insights on Gene Therapy for International Batten Awareness Day CGTLive®

Sarepta defeats Regenxbio, UPenn patent lawsuit over muscular dystrophy treatment Reuters

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III Genetic Engineering and Biotechnology News

Building Manufacturing Capabilities for Adenoassociated Virus Vectors BioProcess International

Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors Frontiers

Regenxbio debuts $65M gene therapy manufacturing facility at its Maryland HQ Fierce Pharma

Viral Clearance in a Downstream AAV Process: Case Study Using a Model Virus Panel and a Noninfectious Surrogate BioProcess International

Check out Regenxbio's stock price (RGNX) in real time CNBC